Alemtuzumab [clinicaltrials_resource:fda7589686ab6989e10fd46ad725bf5c]
clinicaltrials:NCT00001984clinicaltrials:NCT00004143clinicaltrials:NCT00004857Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia [clinicaltrials:NCT00006390]Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia [clinicaltrials:NCT00021151]clinicaltrials:NCT00027560Safety and Efficacy of Campath in Nonmyeloablative Transplantation [clinicaltrials:NCT00038844]Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies [clinicaltrials:NCT00038883]Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies [clinicaltrials:NCT00040846]Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia [clinicaltrials:NCT00046683]clinicaltrials:NCT00047060Stem Cell Transplantation for Patients With Graft Failure Following an Allogeneic Transplant, Using Identical or Near Identical Donors and Less Toxic Conditioning With CAMPATH 1H [clinicaltrials:NCT00048399]Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H [clinicaltrials:NCT00048412]clinicaltrials:NCT00050778Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma [clinicaltrials:NCT00051701]clinicaltrials:NCT00056966Monoclonal Antibody Conditioning for Allogeneic Stem Cell Transplantation of Patients With Inherited Metabolic Storage Diseases [clinicaltrials:NCT00056979]clinicaltrials:NCT00057967clinicaltrials:NCT00058825clinicaltrials:NCT00061048clinicaltrials:NCT00061568clinicaltrials:NCT00061945clinicaltrials:NCT00065260clinicaltrials:NCT00069992clinicaltrials:NCT00071396Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation [clinicaltrials:NCT00073879]Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL [clinicaltrials:NCT00077961]clinicaltrials:NCT00078559Alemtuzumab to Treat Sporadic Inclusion Body Myositis [clinicaltrials:NCT00079768]Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia [clinicaltrials:NCT00081068]clinicaltrials:NCT00085449clinicaltrials:NCT00086580Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia [clinicaltrials:NCT00086775]Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia [clinicaltrials:NCT00089349]clinicaltrials:NCT00098670Continuous Infusion of Campath-1H Followed by Subcutaneous Injections in Previously Treated Patients With Chronic Lymphocytic Leukemia [clinicaltrials:NCT00102661]Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer [clinicaltrials:NCT00104975]clinicaltrials:NCT00105235clinicaltrials:NCT00109993Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies [clinicaltrials:NCT00113048]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
Alemtuzumab [clinicaltrials_resource:fda7589686ab6989e10fd46ad725bf5c]
Bio2RDF identifier
fda7589686ab6989e10fd46ad725bf5c
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:fda7589686ab6989e10fd46ad725bf5c
identifier
clinicaltrials_resource:fda7589686ab6989e10fd46ad725bf5c
title
Alemtuzumab
@en
type
label
Alemtuzumab [clinicaltrials_resource:fda7589686ab6989e10fd46ad725bf5c]
@en